Search

Your search keyword '"Bianco, Ar"' showing total 84 results

Search Constraints

Start Over You searched for: Author "Bianco, Ar" Remove constraint Author: "Bianco, Ar" Topic breast neoplasms Remove constraint Topic: breast neoplasms
84 results on '"Bianco, Ar"'

Search Results

1. Risk factors for joint symptoms in patients enrolled in the ATAC trial: a retrospective, exploratory analysis.

2. Taxane-based combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trials.

Catalog

Books, media, physical & digital resources

3. Phase II study of gefitinib in combination with docetaxel as first-line therapy in metastatic breast cancer.

4. The ATAC ('Arimidex', Tamoxifen, Alone or in Combination) adjuvant breast cancer trial: first results of the endometrial sub-protocol following 2 years of treatment.

5. Zoledronic acid cooperates with a cyclooxygenase-2 inhibitor and gefitinib in inhibiting breast and prostate cancer.

6. A meta-analysis on the interaction between HER-2 expression and response to endocrine treatment in advanced breast cancer.

7. A randomised factorial trial of sequential doxorubicin and CMF vs CMF and chemotherapy alone vs chemotherapy followed by goserelin plus tamoxifen as adjuvant treatment of node-positive breast cancer.

8. The ATAC ('Arimidex', Tamoxifen, Alone or in Combination) adjuvant breast cancer trial: baseline endometrial sub-protocol data on the effectiveness of transvaginal ultrasonography and diagnostic hysteroscopy.

9. Targeting c-erbB2 and other receptors of the c-erbB family: rationale and clinical applications.

10. The ATAC adjuvant breast cancer trial in postmenopausal women: baseline endometrial subprotocol data.

11. Twenty-year results of the Naples GUN randomized trial: predictive factors of adjuvant tamoxifen efficacy in early breast cancer.

12. Combined targeted inhibition of bcl-2, bcl-XL, epidermal growth factor receptor, and protein kinase A type I causes potent antitumor, apoptotic, and antiangiogenic activity.

13. p53 expression is decreased in primary breast carcinomas with microsatellite instability.

14. ZD1839 (IRESSA), an EGFR-selective tyrosine kinase inhibitor, enhances taxane activity in bcl-2 overexpressing, multidrug-resistant MCF-7 ADR human breast cancer cells.

15. Differential TAG-72 epitope expression in breast cancer and lymph node metastases: a marker of a more aggressive phenotype.

16. Oral administration of a novel taxane, an antisense oligonucleotide targeting protein kinase A, and the epidermal growth factor receptor inhibitor Iressa causes cooperative antitumor and antiangiogenic activity.

18. BRCA1 and BRCA2 mutations in central and southern Italian patients.

19. Vinorelbine + mitomycin C as second-line treatment of metastatic breast cancer: a two-stage phase 2 study.

20. A prognostic model that makes quantitative estimates of probability of relapse for breast cancer patients.

21. TAG-72 expression and clinical outcome in primary breast cancer.

22. Measurement of neovascularization is an independent prognosticator of survival in node-negative breast cancer patients with long-term follow-up.

23. The impact of schedule on acute toxicity and dose-intensity of high-dose chemotherapy with epirubicin and cyclophosphamide plus colony stimulating factors in advanced breast cancer.

24. Cooperative inhibitory effect of novel mixed backbone oligonucleotide targeting protein kinase A in combination with docetaxel and anti-epidermal growth factor-receptor antibody on human breast cancer cell growth.

25. Novel deletion at codon 1254 of the BRCA1 gene in an Italian breast cancer kindred.

26. Down-regulation of type I protein kinase A by transfection of human breast cancer cells with an epidermal growth factor receptor antisense expression vector.

27. c-erbB2 expression predicts tamoxifen efficacy in breast cancer patients.

28. Microsatellite instability is correlated with lymph node-positive breast cancer.

29. c-erb B2 overexpression decreases the benefit of adjuvant tamoxifen in early-stage breast cancer without axillary lymph node metastases.

30. A predictive index of axillary nodal involvement in operable breast cancer.

31. Differential immunohistochemical detection of transforming growth factor alpha, amphiregulin and CRIPTO in human normal and malignant breast tissues.

32. Differential sensitivity to non-major histocompatibility complex-restricted recombinant interleukin 2-activated lymphocyte killing of human mammary epithelial MCF-10A cells overexpressing oncogenes or protein kinase A subunits.

33. Selecting high-risk early breast cancer patients: what to add to the number of metastatic nodes?

34. First-line systemic therapy for metastatic breast cancer and management of pleural effusion.

36. Adjuvant chemotherapy in breast cancer.

37. Microsatellite instability and pathological aspects of breast cancer.

38. Cooperative antiproliferative effects of 8-chloro-cyclic AMP and 528 anti-epidermal growth factor receptor monoclonal antibody on human cancer cells.

39. Mitomycin C and mitoxantrone in anthracycline-pretreated advanced breast cancer patients. A phase II study.

40. Endocrine factors in the outcome of systemic adjuvant therapy of early breast cancer.

41. Chemotherapy with mitomycin C and vinblastine in pretreated metastatic breast cancer.

43. Goserelin depot in the treatment of premenopausal advanced breast cancer.

44. Additive effects of c-erbB-2, c-Ha-ras, and transforming growth factor-alpha genes on in vitro transformation of human mammary epithelial cells.

45. Prognostic role of amenorrhea induced by adjuvant chemotherapy in premenopausal patients with early breast cancer.

46. LH-RH analogue Zoladex in the treatment of pre- and perimenopausal women with metastatic breast cancer (results of the Italian Cooperative Study).

47. Impact of preoperative CA 15-3 levels in operable breast cancer. Comparison with tissue polypeptide antigen (TPA) and carcinoembryonic antigen (CEA).

48. Verapamil upregulates sensitivity of human colon and breast cancer cells to LAK-cytotoxicity in vitro.

49. Prolactin receptor does not correlate with oestrogen and progesterone receptors in primary breast cancer and lacks prognostic significance. Ten year results of the Naples adjuvant (GUN) study.

50. Steroid hormone receptor levels and adjuvant tamoxifen in early breast cancer. Ten year results of the Naples (GUN) Study.